41
NEW CONSENSUS ON NON-CIRRHOTIC PORTAL FIBROSIS (NCPF) GUIDE: DR.ATUL SHENDE CANDIDATE:DR.SARATH MENON.R DIVISION OF GASTROENTEROLOGY MGM MEDICAL COLLEGE,INDORE

New consensus on ncpf

Embed Size (px)

DESCRIPTION

Non cirrhotic portal fibrosis

Citation preview

Page 1: New consensus on ncpf

NEW CONSENSUS ON NON-CIRRHOTIC PORTAL FIBROSIS (NCPF)GUIDE: DR.ATUL SHENDE

CANDIDATE:DR.SARATH MENON.R

DIVISION OF GASTROENTEROLOGY

MGM MEDICAL COLLEGE,INDORE

Page 2: New consensus on ncpf

INTRODUCTION NON-CIRRHOTIC PORTAL HYPERTENSION

NCPF

CONCEPT & TERMINOLOGY

NCPF vs EHPVO vs CIRRHOSIS

CLINICAL PROFILE

DIAGNOSIS

MANAGEMENT

PROGNOSIS

Page 3: New consensus on ncpf

NON-CIRRHOTIC PORTAL HYPERTENSION

Increase in portal pressure due to pre-sinusoidal (intra-hepatic) or pre hepatic lesions

Absence of cirrhosis

Absence of hepatic venous outflow obstn.

Vascular lesions

WHVP(wedge hepatic venous pressure) is normal

NCPF & EHPVO- 2 main causes

Page 4: New consensus on ncpf
Page 5: New consensus on ncpf
Page 6: New consensus on ncpf

NCPF - DEFINITION

Disease of uncertain etiology Portal fibrosis & invlv. small and med.portal

veins Portal hypertension,splenomegaly,variceal

bleed. Liver functions & stucture- normal

Page 7: New consensus on ncpf

TERMINOLOGY

Non –cirrhotic portal fibrosis by ICMR in 1969

Idiopathic portal hypertension in Japan

Hepato portal sclerosis in West

Page 8: New consensus on ncpf

NCPF

Indian subcontinent

Low socio-economic status

Age gp- 25-35 yrs

No sex prediliction

Page 9: New consensus on ncpf

ETIOLOGY

Infections – bacterial inf. From gut. - umblical sepsis,diarrhoea in infancy & early childhood. chronic arsenicosis Auto- immune disorders Vinyl chloride Pro-thrombotic state (west)

Exact etiology is still unknown

Page 10: New consensus on ncpf

infections/other agents

chronic/ mild in Later age

c/c antigenenemia/endotoxemia

phlebosclerosis

pre-sinusoidal fibrosis

pre-sinusoidal resistance

PORTAL HYPERTENSION

Page 11: New consensus on ncpf

CLINICAL PROFILE

Age – 2nd and 3rd decades M=F Hemetemesis & malaena (well-tolerated) Feeling of lump Esophagial varices Gastric varices Portal gastropathy Transient ascites

Page 12: New consensus on ncpf

NATURAL HISTORY

Bleeding rate from varices high Mortality is low due to preserved liver

functions. Transient ascites after bleed

Page 13: New consensus on ncpf

HISTOPATHOLOGY

Liver size & structure normal Obliterative portovenopathy -patchy & segmental subendothelial thickening of med & small portal vein - obliteration of small portal veins &

emerg. new abberant portal channels

Page 14: New consensus on ncpf

INVESTIGATIONS

LFT- normal or near normal Pancytopenia due to hypersplenism Bone marrow –hypercellular Coagulation profile and PLC- mild derranged Needle biopsy- - absence of regenerative

nodules - small portal vein obliteration - portal tract fibrosis - perivenular fibrosis - lack of hepatocellular injury

Page 15: New consensus on ncpf

IMAGING

Usg- porto splenic axis dilated & patent - occ.thrombus in intrahepatic branch - echogenic boundary of PV (wall

thickness)

Page 16: New consensus on ncpf
Page 17: New consensus on ncpf

ENDOSCOPY

Esophagial varices – 80-95% Varices are large at time of diagnosis Gastric varices Portal hypertensive gastropathy- rare Anorectal varices common

Page 18: New consensus on ncpf

HEMODYNAMICS

Wedge hepatic venous pressure is normal (WHVP)

Hepatic venous pressure gradient is normal ( WHFP- FHVP)

Page 19: New consensus on ncpf
Page 20: New consensus on ncpf

DIAGNOSTIC FEATURES

Presence of mod- massive splenomegaly Evidence of portal hypertension,varices

and /or collaterals Patent speno-portal axis & hepatic veins on

ultrasound color doppler Normal or near normal liver functions Wedge hepatic venous pressure gradient-

normal Liver histology- no cirrhosis & parenchymal injury

Page 21: New consensus on ncpf

OTHER FEATURES

Absence of signs of CLD No decompensation except transient ascites Absence of serum markers of hep B &C No known etiology of liver disease USG – DILATED & THICKENED portal vein with peripheral pruning &

hyperechoic areas.

Page 22: New consensus on ncpf

DIFFERENTIAL DIAGNOSIS

EHPVO

Idiopathic portal hypertension( Japan)

Incomplete septal cirrhosis

Childs A compensated cirrhosis

Page 23: New consensus on ncpf

parameter EHPVO NCPF Cirrhosis

Median age 10 yr 28 yr 40 yr

Ascites Absent/transientafter bleed

Absent/transient after bleed

+ to +++

Encephalopathy nil nil ++

Jaundice/signs of liver failure

nil nil ++

Liver function test

normal normal deranged

Liver –Gross normal normal Shrunken,nodular

microscopic normal Normal/portal fibrosis

Necrosis,regeneration

Usg Portal/splenic vein block & cavernoma

dilated & patent&thickenedSpleno-portal axis

Dilated & patentSpleno-portal axis

Page 24: New consensus on ncpf

DIFFERENTIALS

Incomplete septal cirrhosis Compensated cirrhosis diagnosed - LIVER BIOPSY

Page 25: New consensus on ncpf

NCPF VS IPH

NCPF IPH

Age (years) 25-35 43-56

M: F 1:1 1:3

Hemetemesis/ malena 94 % 40%

Spenomegaly Dispropationate & massive

moderate

Autoimmune features rare common

Wedge hepatic venous pressure

normal Mildly raised

Geography Indian subcontinent Japan

Page 26: New consensus on ncpf

COMPLICATIONS

Varices

Portal biliopathy

Portal colopathy

Portal gastropathy

Page 27: New consensus on ncpf
Page 28: New consensus on ncpf

PORTAL BILIOPATHY

Term introduced in 1992. Abnormalities of extra & intra hepatic bile

ducts with portal hypertension - identation by paracholedochal collaterals - localized strictures,angulation of duct - displc. Duct,focal narrowing,dilations left hepatic duct (mc) Symptoms- abd.pain,jaundice,fever complication- cholangitis,choledocholithiasis

Page 29: New consensus on ncpf

PORTAL HYPERTENSIVE GASTROPATHY

Rare in NCPF Gastric mucosal & sub mucosal vascular

ectasia Potential for acute & c/c bleeding endoscopy- mosaic or snake skin pattern

mucosa

Page 30: New consensus on ncpf
Page 31: New consensus on ncpf

PORTAL COLOPATHY

Enlarged hemorrhoids

Rectal varices

endoscopy- diffuse vascular ectasia

Page 32: New consensus on ncpf
Page 33: New consensus on ncpf

MANAGEMENT OF ACUTE BLEEDING General management (icu ) - I v fluids, NGT, - blood transfusions Pharmocological therapy- - octreotide,vasopressin - efficacy in NCPF is not known Endoscopic therapy- sclerotherapy & band ligation 80- 90% efficacy band ligation (preffered)

Combination therapy- more effective in acute bleed - prevent rebleed

Page 34: New consensus on ncpf
Page 35: New consensus on ncpf

SCREENING

All patients with moderative- massive splenomegaly with NCPF should have a screening endoscopy

Page 36: New consensus on ncpf

PRIMARY PROPHYLAXIS Beta blockers Endoscopic therapy Combination of both- more effective Shunt sx – if large esophageal varices with symptomatic splenomegaly, thrombocytopenia <20,000, repeated splenic infarcts Gastric varices- - cyanoacrylate glue injection

Page 37: New consensus on ncpf

SECONDARY PROPYLAXIS (RE-BLEEDING)

Endoscopic therapy

Shunt surgery

Page 38: New consensus on ncpf

MANAGEMENT OF SPECIAL SITUATIONS

Hypersplenism- splenectomy in symptomatic done with shunt sx.

Portal biliopathy – cholangitis & choledocholithiasis- - biliary

stenting,sphincterectomy, stone extraction.

Page 39: New consensus on ncpf

PROGNOSIS

Excellent Mortality from acute bleed is lower After successful eradication of

esophagicgastro varices- 2- 5 yr survival is 100%

Page 40: New consensus on ncpf

CONCLUSION

Common cause of PHT in indian subcontinent

Socially disadvantaged people Multifactorial etiogenesis Splenomegaly with complications of PTH & well preserved liver function Diagnosis- clinical,imaging,histology Proper management,life expectancy is

normal Since 1990, there is decline in occurence

Page 41: New consensus on ncpf